PharmaShots | Incisive News in 3 Shots

Subscribe Now

FeDeriCa Study

Roche Reports Results of Fixed-Dose SC Combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) in P-III FeDeriCa Study for HER2-Positive Breast Cancer

Roche Reports Results of Fixed-Dose SC Combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) in P-III FeDeriCa Study for...

December 12, 2019

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

September 13, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us